Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

PDS Biotechnology shares declined after it issued an update about a cancer study with a combination of Versamune HPV and pembrolizumab and reported quarterly results. The stock was down 18%, to $2.25, ...

More sarcoma patients are beating the odds with pembrolizumab! This immunotherapy can change the treatment for limb sarcomas ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

with pembrolizumab treatment offered for 1 year with the option of a second year based on patient and physician preference.

Fecal microbiota transplantation has significantly improved progression-free survival in patients with metastatic renal cell ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

As expected, serious adverse events were more frequent in the experimental group (56%) compared with the control group (31%), ...